Heart risks from newer blood cancer drugs (acalabrutinib or zanubrutinib)
Treatments studied
Part of Heart & circulation clinical trials.
This study looks for early signs of heart problems in people taking newer targeted blood cancer drugs called acalabrutinib or zanubrutinib. By using special blood tests, doctors hope to catch and manage heart issues before they become serious.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You are scheduled to start treatment with acalabrutinib or zanubrutinib for a blood cancer
- You have not taken any other Bruton tyrosine kinase inhibitors before (like ibrutinib or the same drugs)
- You do not have a history of atrial fibrillation (a type of irregular heartbeat)
- Your blood pressure is well-controlled
- You can give written permission (or have a representative who can)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a targeted medicine called zanubrutinib in people aged 80 and older who have chronic lymphocytic leukemia (CLL) that has not been treated yet. It aims to see if this medication can control the disease while being safe and manageable for older adults.
This study looks at whether two newer drugs for blood cancers, zanubrutinib and acalabrutinib, might increase the risk of an irregular heartbeat (atrial fibrillation). It aims to help doctors understand the heart risks of these treatments.
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
Hear when a new Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.